Clobetasol Side Effects
The utmost caution must be used when it comes to applying Clobetasol as there are a list of very serious adverse side effects.
- Osteoporosis
- Acneiform eruptions
- Allergic contact dermatitis
- Burning sensation
- Cracking and fissuring
- Cushing’s syndrome
- Dizziness
- Dryness
- Erythema
- Glaucoma
- Folliculitis
- Hypertrichosis
- Hypopigmentation
- Itching
- Irritation
- Mialiria
- Numbness of the fingers
- Perioral dermatitis
- Pruritis
- Secondary infection
- Skin atrophy
- Skin maceration
- Stinging
- Striae
- Telangiectasia
Pregnant women are strongly discouraged from taking this drug as there is the high risk factor of birth defects.
Warnings & Recalls for Clobetasol
Before using Clobetasol,
- tell your doctor and pharmacist if you are allergic to clobetasol propionate or any other drugs.
- tell your doctor and pharmacist what prescription and nonprescription medications you are using, including vitamins and nutrional supplements.
- tell your doctor if you are pregnant, plan on becoming pregnant, or are nursing. Women who are pregnant are dissuaded from taking Clobetasol as there’s a high risk for birth defects.
In November 2010, the FDA approved safety labeling changes to prescription Clobetasol Propionate as there were post-marketing side effects such as erythema, pruritus, burning, alopecia, and dryness.
Clobetasol Treatment and Use
Clobetasol | Clobetasol Propionate is a corticosteroid that’s used to treat skin disorders such as psoriasis, eczema and contact dermatitis caused by exposure to poison ivy or poison oak. It can also be used to treat several autoimmune diseases such as vitiligo, alopecia areata and lichen planus. Clobetasol belongs to the classification US Class I of corticosteroids which makes it one of the potent in the market. It can come in creams, mousse, shampoos or ointments. Its use is not meant to be extended for more than two weeks.
Other Names for Clobetasol
Clobetasol Propionate
Lawsuits & Legal Information for Clobetasol
Author:
Lainee Hooks
Posted on May 27, 2012
